logo-loader
viewMedlab Clinical Ltd

Medlab Clinical executes exclusive distribution agreement to expand into the UK

Medlab continues the offshore expansion of its nutraceuticals business with a UK partner following its US initiative announced in October.

Medlab Clinical Ltd - Medlab Clinical executes exclusive distribution agreement with nutritional supplement manufacturer Cultech Ltd
Medlab is developing therapies for pain management, depression and obesity

Medlab Clinical Ltd (ASX:MDC) has executed a distribution agreement with nutritional supplement manufacturer Cultech Ltd that will see the company expand its nutraceutical business into the UK.

This exclusive distribution agreement follows the recent execution of a definitive agreement to expand Medlab's nutraceutical business in the USA.

Similar to the previous US deal, the UK agreement provides minimal operating expenditure exposure for Medlab and provides for 20% royalties ex-factory under the transfer agreement.

This agreement focuses on two unique Medlab products:

  • ORSBiotic™: Part of the existing Medlab Australian and US nutraceutical ranges, a patented probiotic rehydration formulation.
  • NanoCBD™: A new cannabinoid product utilising Magnesium and CBD from the newly manufactured NanoCBD™ product - the product utilises Medlab’s patented delivery platform, NanoCelle™.

Both products are expected to be online within the next three months.

 “Uniquely placed to expand trade”

The company's chief executive officer Sean Hall said: “Our IP has commercial reality and whilst we have medical and scientific validation, the real-world validation is the commercial opportunities.

“Medlab remains true to its IPO promise of finding good partners to provide longevity in commercial relationships.

“Regarding Cultech, I have worked with them for well over a decade and they are uniquely placed to expand trade into territories beyond the United Kingdom.”

Premium quality manufacturer

Established in 1994, Cultech has become internationally recognised as both an innovator and premium quality manufacturer within the nutritional supplement industry.

The powerful combination of research scientists together with formulation, process and production technologies enables Cultech to provide a fully integrative manufacturing service, involving unique formulations, innovative presentation and high-quality finished products.

Quick facts: Medlab Clinical Ltd

Price: 0.145 AUD

ASX:MDC
Market: ASX
Market Cap: $40.55 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Medlab Clinical Ltd named herein, including the promotion by the Company of Medlab Clinical Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Medlab Clinical's Dr Sean Hall details new FeverMates agreement

Medlab Clinical Ltd's (ASX:MDC) Dr Sean Hall caught up with Proactive's Andrew Scott after signing a Heads of Agreement (HoA) with Randall Communications Pty Ltd - trading as FeverMates. The deal will help to expand Medlab’s nutraceutical business in new foreign and domestic...

on 6/4/20

2 min read